What If Oncology Evidence Could Move as Fast as We're Learning?

Published on

November 16, 2026

By

Flatiron Health

Flatiron Health's Chris Mader discusses the opportunity to bring real-world insights into cancer research and care faster.

Clinical trials tell us a great deal about how cancer treatments work, but they can't capture the experience of every patient who will eventually receive them. Once a therapy reaches the market, it can take years to gather, analyze and publish evidence about how it performs across broader patient populations.

Chris Mader, our Head of Strategy at Flatiron Health, has seen that challenge from both sides. A former drug development scientist, he understands the time it takes to bring new therapies to patients and the limitations of traditional evidence generation.

At the 2026 STAT Summit, Chris joined Jesse McQuarters of STAT Brand Studio to discuss how real-world data and AI could help change that timeline. Their conversation explored the value of learning from patients treated in both community and academic settings, using AI to identify patterns and generate new research questions, and making those insights more accessible to clinicians.

The opportunity goes beyond generating evidence faster. Learning from a broader range of patient experiences could help researchers design better trials, identify unmet medical needs and give physicians more relevant information when making treatment decisions. The challenge is making those insights available while they're still useful, rather than years down the road.

Watch the full conversation.

Share

Posted in